Huddinge, Sweden

John Löfblom

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Huddinge, SE (2017 - 2020)
  • Tullinge, SE (2021)

Company Filing History:


Years Active: 2017-2021

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of John Löfblom

Introduction

John Löfblom is a distinguished inventor based in Huddinge, Sweden. With a career marked by five patents, Löfblom has significantly contributed to the fields of biotechnology and therapeutic agents. His innovative work revolves around engineered polypeptides, which have promising applications in the diagnosis and treatment of various medical conditions.

Latest Patents

Among his notable patents, the Alzheimer's Aβ peptide binding polypeptide stands out. This invention relates to a class of engineered polypeptides designed to have a binding affinity for amyloid β (Aβ) peptides. The polypeptide features the amino acid sequence EXXYXXNLXAXQLCAXIXXXED (SEQ ID NO:632). The significance of this patent lies in its potential use as therapeutic, prognostic, and diagnostic agents in battling Alzheimer's disease.

Another notable patent involves engineered polypeptides that bind to the neonatal Fc receptor (FcRn). The FcRn binding polypeptide is characterized by the sequence EXXXAXXEIRWLPNLXXXQRXAFIXXLXX. This invention aims to modify the pharmacokinetic and pharmacodynamic properties of therapeutic agents, enhancing their effectiveness.

Career Highlights

Throughout his career, John Löfblom has collaborated with prominent companies, including Affibody AB and Amylonix AB. His work at these organizations has provided him a platform to innovate and develop groundbreaking technologies in the realm of peptide-based therapeutics.

Collaborations

Löfblom has worked alongside esteemed colleagues, such as Elin Gunneriusson and Stefan Ståhl. Together, they have pushed the boundaries of scientific research, contributing valuable advancements to the field of biotechnology.

Conclusion

John Löfblom's contributions to the field of inventing engineered polypeptides demonstrate a clear commitment to innovation. With a strong foundation in biotechnology and a focus on improving therapeutic approaches, Löfblom continues to make strides that could potentially alter the landscape of medical science for the better.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…